达安基因：公司业绩变动主要受集采等医保控费政策及外部宏观市场环境变化等多重因素叠加影响

Core Viewpoint - The company, Da An Gene (002030), indicated that its 2025 annual performance forecast is based on preliminary calculations by the finance department, with performance fluctuations influenced by multiple factors including centralized procurement and healthcare cost control policies, as well as changes in the external macroeconomic environment [1] Financial Performance - The company is taking measures to address operational challenges by focusing on sustainable development and maximizing shareholder interests, which includes implementing cost-saving initiatives and enhancing operational efficiency [1] - The company has recognized impairment indicators for certain assets and has made provisions for asset impairment to solidify asset quality [1] - Final financial data will be disclosed in the officially audited 2025 annual report [1]